157 related articles for article (PubMed ID: 37421211)
1. Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly.
Ruiz S; Gil J; Biagetti B; Venegas E; Cámara R; Garcia-Centeno R; Gálvez MÁ; Picó A; Maraver S; González I; Abellán P; Trincado P; Herrera M; Olvera P; Xifra G; Bernabeu I; Serra-Soler G; Azriel S; García L; Carvalho D; Jordà M; Valassi E; Puig J; Puig-Domingo M
Clin Endocrinol (Oxf); 2023 Oct; 99(4):378-385. PubMed ID: 37421211
[TBL] [Abstract][Full Text] [Related]
2. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly.
Coopmans EC; Schneiders JJ; El-Sayed N; Erler NS; Hofland LJ; van der Lely AJ; Petrossians P; Potorac J; Muhammad A; Neggers SJCMM
Eur J Endocrinol; 2020 Jun; 182(6):595-605. PubMed ID: 32375119
[TBL] [Abstract][Full Text] [Related]
3. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.
Potorac I; Petrossians P; Daly AF; Alexopoulou O; Borot S; Sahnoun-Fathallah M; Castinetti F; Devuyst F; Jaffrain-Rea ML; Briet C; Luca F; Lapoirie M; Zoicas F; Simoneau I; Diallo AM; Muhammad A; Kelestimur F; Nazzari E; Centeno RG; Webb SM; Nunes ML; Hana V; Pascal-Vigneron V; Ilovayskaya I; Nasybullina F; Achir S; Ferone D; Neggers SJ; Delemer B; Petit JM; Schöfl C; Raverot G; Goichot B; Rodien P; Corvilain B; Brue T; Schillo F; Tshibanda L; Maiter D; Bonneville JF; Beckers A
Endocr Relat Cancer; 2016 Nov; 23(11):871-881. PubMed ID: 27649724
[TBL] [Abstract][Full Text] [Related]
4. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly.
Heck A; Ringstad G; Fougner SL; Casar-Borota O; Nome T; Ramm-Pettersen J; Bollerslev J
Clin Endocrinol (Oxf); 2012 Jul; 77(1):72-8. PubMed ID: 22066905
[TBL] [Abstract][Full Text] [Related]
5. Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study.
Ilie MD; Tabarin A; Vasiljevic A; Bonneville JF; Moreau-Grangé L; Schillo F; Delemer B; Barlier A; Figarella-Branger D; Bisot-Locard S; Santos A; Chanson P; Raverot G
J Clin Endocrinol Metab; 2022 Nov; 107(11):2982-2991. PubMed ID: 36136828
[TBL] [Abstract][Full Text] [Related]
6. Pasireotide in the Personalized Treatment of Acromegaly.
Puig-Domingo M; Bernabéu I; Picó A; Biagetti B; Gil J; Alvarez-Escolá C; Jordà M; Marques-Pamies M; Soldevila B; Gálvez MA; Cámara R; Aller J; Lamas C; Marazuela M
Front Endocrinol (Lausanne); 2021; 12():648411. PubMed ID: 33796079
[TBL] [Abstract][Full Text] [Related]
7. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
Sheppard M; Bronstein MD; Freda P; Serri O; De Marinis L; Naves L; Rozhinskaya L; Hermosillo Reséndiz K; Ruffin M; Chen Y; Colao A
Pituitary; 2015 Jun; 18(3):385-94. PubMed ID: 25103549
[TBL] [Abstract][Full Text] [Related]
8. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
Colao A; Bronstein MD; Freda P; Gu F; Shen CC; Gadelha M; Fleseriu M; van der Lely AJ; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Sheppard M;
J Clin Endocrinol Metab; 2014 Mar; 99(3):791-9. PubMed ID: 24423324
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure.
Puig-Domingo M; Resmini E; Gomez-Anson B; Nicolau J; Mora M; Palomera E; Martí C; Halperin I; Webb SM
J Clin Endocrinol Metab; 2010 Nov; 95(11):4973-8. PubMed ID: 20739382
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
11. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
[TBL] [Abstract][Full Text] [Related]
12. Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience.
Gadelha M; Marques NV; Fialho C; Scaf C; Lamback E; Antunes X; Santos E; Magalhães J; Wildemberg LE
J Clin Endocrinol Metab; 2023 Nov; 108(12):e1571-e1579. PubMed ID: 37357993
[TBL] [Abstract][Full Text] [Related]
13. T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective.
Potorac I; Beckers A; Bonneville JF
Pituitary; 2017 Feb; 20(1):116-120. PubMed ID: 28197813
[TBL] [Abstract][Full Text] [Related]
14. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
[TBL] [Abstract][Full Text] [Related]
15. The Effect of 6 Months' Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings.
Witek P; Bolanowski M; Szamotulska K; Wojciechowska-Luźniak A; Jawiarczyk-Przybyłowska A; Kałużny M
Front Endocrinol (Lausanne); 2021; 12():633944. PubMed ID: 33776927
[TBL] [Abstract][Full Text] [Related]
16. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
17. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly.
Schmid HA; Brue T; Colao A; Gadelha MR; Shimon I; Kapur K; Pedroncelli AM; Fleseriu M
Endocrine; 2016 Jul; 53(1):210-9. PubMed ID: 26906713
[TBL] [Abstract][Full Text] [Related]
18. Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.
Samson SL
Neuroendocrinology; 2015; 102(1-2):8-17. PubMed ID: 25792118
[TBL] [Abstract][Full Text] [Related]
19. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
20. Pasireotide: potential treatment option for McCune-Albright-associated acromegaly.
Ilie MD; Raverot G; Brac de la Perrière A
Eur J Endocrinol; 2024 Jan; 190(1):K17-K20. PubMed ID: 38128124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]